These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16732136)

  • 1. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
    Preskorn SH
    J Psychiatr Pract; 2006 May; 12(3):168-72. PubMed ID: 16732136
    [No Abstract]   [Full Text] [Related]  

  • 2. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal selegiline: a novel MAOI formulation for depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2006 Jul; 44(7):9-12. PubMed ID: 17310829
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 7. Transdermal selegiline: new opportunity for managing depression.
    Tobe EH
    J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
    [No Abstract]   [Full Text] [Related]  

  • 8. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 10. Selegiline transdermal system in major depressive disorder: profile report.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
    Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
    J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
    Pare CM; Al Mousawi M; Sandler M; Glover V
    J Affect Disord; 1985 Sep; 9(2):137-41. PubMed ID: 2932486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art.
    Rapaport MH
    J Clin Psychiatry; 2007; 68 Suppl 8():42-6. PubMed ID: 17640157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
    Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
    CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
    Mahmood I
    Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline transdermal system: in the treatment of major depressive disorder.
    Frampton JE; Plosker GL
    Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.